Home  /   Products  /   Dermatology  /   Naftifine solution 1% – [10 ml vial]

Naftifine solution 1% – [10 ml vial]


Antifungal drug for external use

SKU: 62186 Category:


Naftifin Pharmacodynamics
Naftifin is an antifungal agent for external use, belonging to the class of allilamines. The mechanism of action is associated with inhibition of squalene-2,3-epoxidase, which leads to a decrease in the formation of ergosterol, which is a part of the cell wall of the fungus. Naftifin, affecting squalene epoxidase, does not affect the cytochrome P-450 system.
It is active against dermatophytes such as Trichophyton, Epidermophyton, Microsporum, yeast and yeast-like fungi (Candida spp., Pityrosporum), mold fungi (Aspergillus spp.) and other fungi (such as Sporothrix schenckii). Against dermatophytes and aspergillus naphthifin acts fungicidal. Against yeast fungi the drug exhibits fungicidal or fungistatic activity depending on the strain of the microorganism. It has antibacterial activity against Gram-positive and Gram-negative microorganisms causing secondary bacterial infections. It has anti-inflammatory action, which contributes to the rapid disappearance of inflammatory symptoms, especially itching.

Fungal infections of the skin and skin folds (tinea corporis, tinea inguinalis);
Interfinger mycoses (tinea manum, tinea pedum);
Fungal infections of the nails (onychomycoses);
skin candidiasis;
Lichen multicolor (pityriasis);
dermatomycoses (with or without associated itching).
The drug is effective in the treatment of mycoses affecting areas of the skin with hyperkeratosis, as well as in hair growth areas.

Hypersensitivity to naphthyphine or other components of the drug; pregnancy and breast-feeding (safety and efficacy of use have not been established); application on the wound surface.
Childhood (clinical experience of use is limited).
Administration during pregnancy and breast-feeding
It is contraindicated in pregnancy and during breast-feeding (safety and efficacy of the drug in this group of patients has not been studied).

Dosage and administration method.

  • Outwardly.
  • When the skin is affected.
  • The drug is applied once a day to the affected skin surface and adjacent areas (about 1 cm of healthy skin at the edges of the affected area) after thorough cleaning and drying.
  • Duration of treatment in dermatomycosis – 2-4 weeks (if necessary – up to 8 weeks), with candidiasis – 4 weeks.
  • When nails are affected.
  • Before the first use of the drug as much as possible remove the affected part of the nail with scissors or a nail file. The drug is applied twice a day to the affected nail.
  • The duration of treatment for onychomycosis is up to 6 months.
  • To prevent recurrence of the infection, treatment should be continued for at least 2 weeks after the disappearance of clinical symptoms.
  • If no improvement occurs after treatment, or if symptoms worsen, or new symptoms appear, consult a doctor. Use the drug only according to the method of application and in the doses stated in the instructions. If necessary, please consult a physician before using the drug.